Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.
about
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusNovel biomarkers of abdominal aortic aneurysm disease: identifying gaps and dispelling misperceptionsTWEAK promotes peritoneal inflammationImmunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndromeNovel methodologies for biomarker discovery in atherosclerosisReduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.Proteomic analysis in cardiovascular diseases.Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilationSerum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis.Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domainSoluble TWEAK independently predicts atherosclerosis in renal transplant patients.Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice.N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery DiseaseHIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease.Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease.Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.Proteomics in atherothrombosis: a future perspective.Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.Vascular proteomics, a translational approach: from traditional to novel proteomic techniques.Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK.Recent advances in proteomic technologies applied to cardiovascular disease.Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis.TWEAK: A New Player in Obesity and Diabetes.Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors.Proteomics in cardiovascular disease: recent progress and clinical implication and implementation.TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB.Characterization of Lamprey BAFF-like Gene: Evolutionary Implications.Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes.
P2860
Q26851535-CCDDC132-8753-4781-A4B6-2233E23E98B8Q27000373-AA029184-5C89-4D2B-8C17-D7C1AFEBEF52Q27318227-2A353565-4DC6-4BE7-8A53-BEA1B4FB8D10Q28071723-580AF102-749F-4339-8E03-9DCA8B4521CDQ28088373-0DBE5E99-8AE0-4B13-A2D6-E58EC3C4BA23Q31152445-C25E4257-0093-4C84-9ED2-533FA1A79934Q33321675-6277DAEF-F2EB-4B97-97D6-9EFA9D1F605CQ33825980-B2ED325D-4F5B-4700-B8A9-D1BD1DADEFF3Q33931813-C245CCDF-CF64-47D3-A280-AAD3B39B44EDQ33944773-ED6E4806-684B-4DAF-A964-3E2FD25B075AQ34399571-C09392F2-6E33-4C26-8264-9C6EAFD3CCB5Q34450860-2440F526-0962-4E57-A07C-72797DCE5D28Q34460820-82A6B802-C03F-456F-A52B-DBD9036E9195Q34751855-0106DE8A-1916-4557-A9D5-4AA7A962CFFCQ34764239-8BCA4DD8-D1A9-4B9E-BCF7-A29EFB33A9B1Q34815993-DF022AEA-5B9D-4B39-9533-426073FBAEE0Q35026182-FB3F39A3-F97F-448F-954A-BDAF2581D929Q35689476-E64C948B-56FA-49A2-A1B0-FF2195A0EC0AQ35866999-F4B4E37A-FD87-4CB9-A54D-6B21EC5D57F8Q35958888-194FD6E9-6B0D-4E10-92F1-EBBF16529917Q36015686-8A49F0C3-DCA3-41FA-9957-F4C040EB1B9FQ36686970-2093D0BA-45D2-4EF7-9696-2D74FF9EFD43Q36787244-9F064776-BCB8-49DA-8F6E-82B1BD83EE30Q37042084-4789E7A4-C660-4D78-92B9-F531A086C79AQ37415728-64E8B3EF-0AFB-41E6-9F8A-B63188CFBF43Q37494039-05924771-3C25-4C0B-ACAB-3ED97840D58AQ37610301-FD6CA465-11FA-4D90-BD67-CAF81FFD5161Q37681640-D30DE8F6-C30A-4E66-BBE6-0F4655277CEAQ37724036-54A05F0D-35FB-4631-B68D-4E9DE8C1DDC3Q37871569-38206125-E2CB-4A68-8F6E-0129BD72D313Q38034137-39BAA342-EDBC-4EDF-8A78-0BC14A66A378Q38106664-6F2F1B83-AFF7-4C0C-8F3C-09BABC39B342Q38177788-3952D6F0-E226-4959-B35C-833EBF6C35FFQ38552059-F77FBBE0-2BDB-46BA-AD46-F25FD7FE94A3Q38614592-FD351FA3-1E3F-4C67-8B2B-75F82BDF9835Q38638020-73E91F0D-ABD7-4652-A2FF-EDA22ABECB4AQ38780174-D02459DD-40F0-465B-B1D5-58A471FDAFC3Q40640099-61A9DAA2-7759-45DD-940F-D4FF28472EE1Q41648597-91650B4D-9A5C-47C6-B266-5014E572A22AQ42492245-DB1796E8-DFE3-47B1-AA9C-A51EFB7CAC60
P2860
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Identification of soluble tumo ...... f subclinical atherosclerosis.
@ast
Identification of soluble tumo ...... f subclinical atherosclerosis.
@en
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis
@nl
type
label
Identification of soluble tumo ...... f subclinical atherosclerosis.
@ast
Identification of soluble tumo ...... f subclinical atherosclerosis.
@en
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis
@nl
prefLabel
Identification of soluble tumo ...... f subclinical atherosclerosis.
@ast
Identification of soluble tumo ...... f subclinical atherosclerosis.
@en
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis
@nl
P2093
P50
P1476
Identification of soluble tumo ...... f subclinical atherosclerosis.
@en
P2093
Begoña Muñóz-García
Jean-Baptiste Michel
Jesús Egido
Jose A Páramo
P304
P356
10.1161/01.ATV.0000258972.10109.FF
P407
P577
2007-02-01T00:00:00Z